The number of people with type 2 diabetes will continue to increase, presenting a huge market for diabetic drugs, from more than 2.3 million cases in 2010 to 2.7 million cases in 2020. The major epidemiologic drivers for diabetes in Australia are population growth, the aging population, increases in underlying obesity, and decreased physical activity.
Features and benefits
* Gain insight to market potential, including a robust 10-year epidemiology forecast of incidence and prevalent cases of diabetes in Australia
* Understand the key epidemiologic risk factors associated with diabetes in Australia
Datamonitor estimates that there will be a marginal increase in the incidence of cases of type 1 diabetes in children under the age of 14 in Australia between 2010 and 2020.
Datamonitor estimates that males aged 10–14 will account for the largest proportion (approximately 23%) of incident cases of type 1 diabetes during the 2010–20 forecast period, followed closely by females of the same age group.
Type 2 diabetes is the more common form of the disease. The number of diagnosed prevalent cases of type 2 diabetes will increase among all age groups in Australia from 2,341,674 cases in 2010 to 2,716,101 cases in 2020.
Your key questions answered
* What are the most robust sources for diabetes in Australia incidence and prevalence data?
* How will the patient population change over the next decade in Australia
* How do changes in population structure and risk factors affect the trend in incidence and prevalent diabetes cases?
Global Leisure Products industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2006-10, and forecast to 2015). The profile also contains descriptions of the leading players including key financial metrics ... more
Global Leisure Facilities industry profile provides top-line qualitative and quantitative summary information including: market size (value , and forecast to 5). The profile also contains descriptions of the leading players including key financial metrics and analysis of compe ... more
In 2010, Datamonitor estimates that there were 7.4 million major abdominal surgeries in the seven major markets. This number is not expected to change significantly, growing to 8.1 million surgeries in 2020.
Features and benefits
* Gain insight to market potential, including ... more
The Australian oncology market’s high value and growth opportunities have made it an attractive arena for drug developers to enter. Top 20 cancer therapy brands sales totaled $545m in Australia in 2008, growing at a CAGR of 30% since 2005. Although this growth is expected to slow down consi ... more
The independent business analyst forecasts that the antidiabetics market will be worth $37 billion by 2018 up from $20 billion in 2008. This rapid market expansion presents significant opportunities for pharmaceutical companies who are able to develop new therapies to address the unmet clin ... more
Pharmaceutical companies will struggle to profit from the cardiovascular disease (CVD) market over the next decade despite growing drug usage, according to Datamonitor. New research by the independent business analyst predicts that the CVD pharma market will grow from $99bn in 2008 to $107b ... more